Condition

Non-small-cell Lung Cancer (NSCLC)

ClinicalTrials.gov condition label

Clinical trials5

Recruiting0

Common interventions8

Lead sponsors shown5

Clinical trials

5 shown

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung CancerNCT06357598 · 2024-01-18

PPIO-006 Primary Tumor Resection for IVa NSCLCNCT06232967 · 2023-04-01

Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLCNCT04338620 · 2020-04-07

A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer PatientsNCT03725475 · 2018-11-26

A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung CancerNCT01874678 · 2011-03-01

Common interventions

albumin-bound paclitaxel and platinumDRUG1 camrelizumab、albumin-bound paclitaxel and platinumDRUG1 Carboplatin or CisplatinDRUG1 Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)DRUG1 Primary tumor resection or notPROCEDURE1 SurgeryPROCEDURE1 TislelizumabDRUG1 TS-1/CisplatinDRUG1

Leading sponsors

AstraZeneca1 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University1 Tang-Du Hospital1 The Affiliated Hospital of Qingdao University1 TTY Biopharm1

Trial status mix

COMPLETED3

UNKNOWN2

Phase mix

NA1

PHASE21

PHASE41

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.